Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients
Cell · 2025-02 · 188 (4) · 1119-1136.e23
DOI: 10.1016/j.cell.2024.12.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2025-02. Verfasst von Liping Zhong und 44 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Targeting Oncology, National Center for International Research of Biotargeting Theranostics, Guangxi Medical University, Nann…. Hauptthemen laut MEDLINE: Oncolytic Virotherapy, Oncolytic Viruses, Newcastle disease virus, Carcinoma, Hepatocellular. Die Arbeit wurde bisher 112-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Recently, oncolytic virus (OV) therapy has shown great promise in treating malignancies. However, intravenous safety and inherent lack of immunity are two significant limitations in clinical practice. Herein, we successfully developed a recombinant Newcastle disease virus with porcine α1,3GT gene (NDV-GT) triggering hyperacute rejection. We demonstrated its feasibility in preclinical studies. The intravenous NDV-GT showed superior ability to eradicate tumor cells in our innovative CRISPR-mediated primary hepatocellular carcinoma monkeys. Importantly, the interventional clinical trial treating 20 patients with relapsed/refractory metastatic cancer (Chinese Clinical Trial Registry of WHO, ChiCTR2000031980) showed a high rate (90.00%) of disease control and durable responses, without serious adverse events and clinically functional neutralizing antibodies, further suggesting that immunogenicity is minimal under these conditions and demonstrating the feasibility of NDV-GT for immunovirotherapy. Collectively, our results demonstrate the high safety and efficacy of intravenous NDV-GT, thus providing an innovative technology for OV therapy in oncological therapeutics and beyond.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- State Key Laboratory of Targeting Oncology, National Center for International Research of Biotargeting Theranostics, Guangxi Medical University, Nanning, Guangxi 530021, China. Electronic address: zhongliping@gxmu.edu.c…
- State Key Laboratory of Targeting Oncology, National Center for International Research of Biotargeting Theranostics, Guangxi Medical University, Nanning, Guangxi 530021, China.
- Department of Spine Surgery, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, China.
- The First People's Hospital of Changde City, Changde, Hunan 415000, China.
- Department of Oncology, The First Affiliated Hospital, Guangxi University of Chinese Medicine, Nanning, Guangxi 530023, China.
- Department of Nuclear Medicine, The Affiliated Tumor Hospital, Guangxi Medical University, Nanning, Guangxi 530021, China.
Zitieren
APA
Zhong, L., Gan, L., Wang, B., Wu, T., Yao, F., Gong, W., Peng, H., Deng, Z., Xiao, G., Liu, X., Na, J., Xia, D., Yu, X., Zhang, Z., Xiang, B., Huo, Y., Yan, D., Dong, Z., Fang, F., …, & Zhao, Y. (2025). Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell, 188(4), 1119-1136.e23. https://doi.org/10.1016/j.cell.2024.12.010
Vancouver
Zhong L, Gan L, Wang B, Wu T, Yao F, Gong W, et al. Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients. Cell. 2025;188(4):1119-1136.e23. doi:10.1016/j.cell.2024.12.010
BibTeX
@article{Zhong2025,
author = {Zhong, Liping and Gan, Lu and Wang, Bing and Wu, Tao and Yao, Fei and Gong, Wenlin and Peng, Hongmei and Deng, Zhiming and Xiao, Guoyou and Liu, Xiyu and Na, Jintong and Xia, Desong and Yu, Xianjun and Zhang, Zhikun and Xiang, Bangde and Huo, Yu and Yan, Dan and Dong, Zhixin and Fang, Fang and Ma, Yun and Jin, Guanqiao and Su, Danke and Liu, Xiuli and Li, Qiang and Liao, Hai and Tang, Chao and He, Jian and Tang, Zhiping and Zhang, Shilai and Qiu, Bingqing and Yang, Zhi and Yang, Lihui and Chen, Ziqin and Zeng, Mengsi and Feng, Ronghua and Jiao, Jiege and Liao, Yuan and Wang, Tinghua and Wu, Liangliang and Mi, Zhengcheng and Liu, Ziqun and Shi, Si and Zhang, Kun and Shi, Wei and Zhao, Yongxiang},
title = {Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients},
journal = {Cell},
year = {2025},
volume = {188},
number = {4},
pages = {1119--1136.e23},
doi = {10.1016/j.cell.2024.12.010}
}
EUVIMED